Navigant study- treatment patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) (Navigant)
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
- Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart. - Patients were at least 18 years of age as of the first diagnosis for mCRPC. - Patients must have received at least one intravenous injection of Radium-223 (Xofigo). - First injection of Radium-223 must have started between periods 1-January-2014 to 30-June-2014 or 15-November-2014 to present. - Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.
- Patients who received Radium-223 as part in an interventional clinical trial - Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.
Whippany, United States, 07981
E-mail: [email protected]
Phone: (+) 1-888-8422937
Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients treated with Radium-223